Gerald A. Posen

TL;DR: The objective of this study was to determine the probabilities of specific morbid events or death among patients with end-stage renal disease treated by hemodialysis, and older age and history of cardiovascular disease were independently associated with a greater probability of death.

TL;DR: Normalization of hemoglobin does not lead to regression of established concentric LV hypertrophy or LV dilation, and it may, however, prevent the development of LV dilated and it leads to improved quality of life.

TL;DR: It is concluded that plasma exchange offers no additional therapeutic benefit to patients with idiopathic rapidly progressive glomerulonephritis (RPGN) who are not dialysis-dependent at presentation.

TL;DR: There is currently no evidence that other products are safer than Ab+ PRCA, and the subcutaneous administration of HSA-containing Eprex is riskier than intravenous Epogen and intravenous HSA/subcutaneous NeoRecormon is riskiest than intravenously Epogen.

TL;DR: Quality of life estimated by a disease-specific Kidney Disease Questionnaire improved significantly during rHuEPO therapy in both groups and there was no significant change in dialysis prescription throughout the study.